Abstract #3390

QSM and T2* Mapping in a Six Month Placebo-Controlled Clinical Trial of the Iron Chelator Deferiprone in Parkinson’s Disease

Rexford Newbould¹, Courtney Bishop¹, Antonio Martin-Bastida², and David Dexter²

¹Imanova Centre for Imaging Sciences, London, United Kingdom, ²Imperial College London, London, United Kingdom

A double-blind placebo-controlled clinical trial of an iron chelation therapy was performed in 25 subjects with Parkinson’s disease (PD) and 12 healthy matched controls. Two MRI measures of brain iron at each of three visits at baseline, 3 months, and 6 months were derived from a high resolution 3D multiecho volume: T2* and QSM maps. T2* values significantly lengthened in six of nine pre-defined ROIs by the final visit in the highest dose group. QSM values , however, did not change with treatment. This differential trajectory between relaxation and susceptibility may result from ferritin’s complex relaxation behavior.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.